Review and risk information management of neuropathy induced by emerging anti-tumor drugs
10.12173/j.issn.1005-0698.202304130
- VernacularTitle:新型抗肿瘤药物致神经系统疾病综述及风险信息管理
- Author:
Feng LYU
1
;
Wei SONG
;
Mengru XIN
;
Di XIE
;
Wenqing ZHANG
;
Wen HE
;
Hankun HU
Author Information
1. 武汉大学人民医院药学部(武汉 430060)
- Keywords:
Emerging anti-tumor drugs;
Drug-induced neuropathy;
Drug risk information management
- From:
Chinese Journal of Pharmacoepidemiology
2024;33(1):9-18
- CountryChina
- Language:Chinese
-
Abstract:
As an increasing number of emerging anti-tumor drugs are approved and marketed,the imperative for clinical safety monitoring and risk information management has grown significantly.Drug-induced neuropathy associated with these drugs exhibit characteristics such as insidious onset,rapid progression,and challenging treatment,ultimately leading to treatment failures.Therefore,a comprehensive understanding of the risk of neuropathy induced by emerging anti-tumor drugs,coupled with risk surveillance and early warning,as well as management and reporting,can significantly reduce the incidence and severity of drug-related diseases.This paper provides a review of the neuropathy caused by emerging anti-tumor drugs,introduces the pharmacovigilance system and risk information management measures in clinical usage,aiming to provide a reference for guiding the rational clinical use and minimizing the incidence of drug-induced diseases.
